Audentes Therapeutics (NASDAQ:BOLD) Receives Daily Coverage Optimism Rating of 0.15

Media headlines about Audentes Therapeutics (NASDAQ:BOLD) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Audentes Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.1693864223557 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several equities research analysts have weighed in on BOLD shares. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 17th. Leerink Swann started coverage on Audentes Therapeutics in a research note on Monday, May 1st. They set an “outperform” rating and a $22.00 price objective on the stock. Wedbush reissued an “ourperform” rating and set a $20.00 price objective on shares of Audentes Therapeutics in a research note on Monday, May 15th. Finally, ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $22.25.

Audentes Therapeutics (NASDAQ:BOLD) opened at 17.50 on Friday. The company has a 50-day moving average price of $19.92 and a 200 day moving average price of $16.80. The company’s market cap is $383.06 million. Audentes Therapeutics has a 52 week low of $13.13 and a 52 week high of $22.82.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, equities research analysts forecast that Audentes Therapeutics will post ($3.46) EPS for the current fiscal year.

In related news, CEO Matthew R. Patterson sold 15,000 shares of Audentes Therapeutics stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $300,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Matthew R. Patterson sold 2,850 shares of Audentes Therapeutics stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,850 shares of company stock worth $653,700. Insiders own 47.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/08/12/audentes-therapeutics-nasdaqbold-earning-somewhat-positive-news-coverage-study-shows-updated.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

What are top analysts saying about Audentes Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit